Do analysts rate SNGX or NEUP?

Neuphoria Therapeutics has a consensus target price of $21.00, suggesting a potential upside of 444.04%. Given Neuphoria Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Neuphoria Therapeutics is more favorable than Soligenix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Soligenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Neuphoria Therapeutics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is SNGX or NEUP more profitable?

Neuphoria Therapeutics' return on equity of -76.93% beat Soligenix's return on equity. Company Net Margins Return on Equity Return on Assets Soligenix N/A -180.25% -107.46% Neuphoria Therapeutics N/A -76.93% -54.76%

Do analysts prefer ALLR or SNGX?

Allarity Therapeutics currently has a consensus price target of $10.25, suggesting a potential upside of 670.68%. Given Allarity Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Allarity Therapeutics is more favorable than Soligenix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Allarity Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Soligenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ALLR or SNGX more profitable?

Allarity Therapeutics' return on equity of -152.77% beat Soligenix's return on equity. Company Net Margins Return on Equity Return on Assets Allarity Therapeutics N/A -152.77% -46.50% Soligenix N/A -180.25% -107.46%

Do analysts rate QNTM or SNGX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Quantum Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Soligenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is QNTM or SNGX more profitable?

Soligenix's return on equity of -180.25% beat Quantum Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Quantum Biopharma N/A -582.23% -184.20% Soligenix N/A -180.25% -107.46%

Do analysts prefer CELU or SNGX?

Celularity presently has a consensus price target of $6.00, suggesting a potential upside of 649.25%. Given Celularity's stronger consensus rating and higher possible upside, equities research analysts plainly believe Celularity is more favorable than Soligenix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Celularity 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Soligenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is CELU or SNGX more profitable?

Soligenix has a net margin of 0.00% compared to Celularity's net margin of -345.45%. Celularity's return on equity of 0.00% beat Soligenix's return on equity. Company Net Margins Return on Equity Return on Assets Celularity -345.45% N/A -77.94% Soligenix N/A -180.25% -107.46%

Do analysts recommend JSPR or SNGX?

Jasper Therapeutics currently has a consensus target price of $8.17, suggesting a potential upside of 1,033.94%. Given Jasper Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Jasper Therapeutics is more favorable than Soligenix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jasper Therapeutics 1 Sell rating(s) 3 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.50 Soligenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is JSPR or SNGX more profitable?

Soligenix's return on equity of -180.25% beat Jasper Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Jasper Therapeutics N/A -884.17% -143.83% Soligenix N/A -180.25% -107.46%

Soligenix (SNGX) Competitors

$0.41 +0.00 (+0.10%)

Closing price 04:00 PM Eastern

Extended Trading

$0.40 0.00 (-0.02%)

As of 05:41 PM Eastern

Compare

SNGX vs. NEUP, ALLR, QNTM, CELU, and JSPR

Should you buy Soligenix stock or one of its competitors? Soligenix's main competitors and comparable companies include Neuphoria Therapeutics (NEUP), Allarity Therapeutics (ALLR), Quantum Biopharma (QNTM), Celularity (CELU), and Jasper Therapeutics (JSPR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Soligenix compare to Neuphoria Therapeutics?

Soligenix (NASDAQ:SNGX) and Neuphoria Therapeutics (NASDAQ:NEUP) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, media sentiment, earnings, analyst recommendations and dividends.

Soligenix has a beta of 1.93, meaning that its stock price is 93% more volatile than the broader market. Comparatively, Neuphoria Therapeutics has a beta of 0.75, meaning that its stock price is 25% less volatile than the broader market.

3.6% of Soligenix shares are owned by institutional investors. Comparatively, 15.9% of Neuphoria Therapeutics shares are owned by institutional investors. 1.9% of Soligenix shares are owned by insiders. Comparatively, 1.5% of Neuphoria Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Neuphoria Therapeutics has higher revenue and earnings than Soligenix. Soligenix is trading at a lower price-to-earnings ratio than Neuphoria Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Soligenix	$120K	50.03	-$11.08M	-$0.98	N/A
Neuphoria Therapeutics	$15.65M	1.33	-$370K	-$11.06	N/A

Neuphoria Therapeutics has a consensus target price of $21.00, suggesting a potential upside of 444.04%. Given Neuphoria Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Neuphoria Therapeutics is more favorable than Soligenix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Soligenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Neuphoria Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Neuphoria Therapeutics' return on equity of -76.93% beat Soligenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Soligenix	N/A	-180.25%	-107.46%
Neuphoria Therapeutics	N/A	-76.93%	-54.76%

In the previous week, Soligenix and Soligenix both had 2 articles in the media. Soligenix's average media sentiment score of 0.00 equaled Neuphoria Therapeutics'average media sentiment score.

Company	Overall Sentiment
Soligenix	Neutral
Neuphoria Therapeutics	Neutral

Summary

Neuphoria Therapeutics beats Soligenix on 9 of the 13 factors compared between the two stocks.

How does Soligenix compare to Allarity Therapeutics?

Allarity Therapeutics (NASDAQ:ALLR) and Soligenix (NASDAQ:SNGX) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and media sentiment.

11.5% of Allarity Therapeutics shares are held by institutional investors. Comparatively, 3.6% of Soligenix shares are held by institutional investors. 0.2% of Allarity Therapeutics shares are held by company insiders. Comparatively, 1.9% of Soligenix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Allarity Therapeutics currently has a consensus price target of $10.25, suggesting a potential upside of 670.68%. Given Allarity Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Allarity Therapeutics is more favorable than Soligenix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allarity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Soligenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Soligenix has lower revenue, but higher earnings than Allarity Therapeutics. Allarity Therapeutics is trading at a lower price-to-earnings ratio than Soligenix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allarity Therapeutics	$320K	66.13	-$11.23M	-$0.78	N/A
Soligenix	$120K	50.03	-$11.08M	-$0.98	N/A

In the previous week, Soligenix had 1 more articles in the media than Allarity Therapeutics. MarketBeat recorded 2 mentions for Soligenix and 1 mentions for Allarity Therapeutics. Allarity Therapeutics' average media sentiment score of 0.00 equaled Soligenix'saverage media sentiment score.

Company	Overall Sentiment
Allarity Therapeutics	Neutral
Soligenix	Neutral

Allarity Therapeutics' return on equity of -152.77% beat Soligenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allarity Therapeutics	N/A	-152.77%	-46.50%
Soligenix	N/A	-180.25%	-107.46%

Allarity Therapeutics has a beta of 0.51, meaning that its stock price is 49% less volatile than the broader market. Comparatively, Soligenix has a beta of 1.93, meaning that its stock price is 93% more volatile than the broader market.

Summary

Allarity Therapeutics beats Soligenix on 9 of the 14 factors compared between the two stocks.

How does Soligenix compare to Quantum Biopharma?

Quantum Biopharma (NASDAQ:QNTM) and Soligenix (NASDAQ:SNGX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quantum Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Soligenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Quantum Biopharma has a beta of 0.45, meaning that its stock price is 55% less volatile than the broader market. Comparatively, Soligenix has a beta of 1.93, meaning that its stock price is 93% more volatile than the broader market.

In the previous week, Quantum Biopharma had 2 more articles in the media than Soligenix. MarketBeat recorded 4 mentions for Quantum Biopharma and 2 mentions for Soligenix. Quantum Biopharma's average media sentiment score of 0.00 equaled Soligenix'saverage media sentiment score.

Company	Overall Sentiment
Quantum Biopharma	Neutral
Soligenix	Neutral

Soligenix has higher revenue and earnings than Quantum Biopharma. Quantum Biopharma is trading at a lower price-to-earnings ratio than Soligenix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quantum Biopharma	N/A	N/A	-$26.17M	-$5.49	N/A
Soligenix	$120K	50.03	-$11.08M	-$0.98	N/A

1.2% of Quantum Biopharma shares are owned by institutional investors. Comparatively, 3.6% of Soligenix shares are owned by institutional investors. 8.5% of Quantum Biopharma shares are owned by company insiders. Comparatively, 1.9% of Soligenix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Soligenix's return on equity of -180.25% beat Quantum Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quantum Biopharma	N/A	-582.23%	-184.20%
Soligenix	N/A	-180.25%	-107.46%

Summary

Soligenix beats Quantum Biopharma on 8 of the 10 factors compared between the two stocks.

How does Soligenix compare to Celularity?

Celularity (NASDAQ:CELU) and Soligenix (NASDAQ:SNGX) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends.

In the previous week, Celularity and Celularity both had 2 articles in the media. Celularity's average media sentiment score of 0.00 equaled Soligenix'saverage media sentiment score.

Company	Overall Sentiment
Celularity	Neutral
Soligenix	Neutral

Soligenix has lower revenue, but higher earnings than Celularity. Soligenix is trading at a lower price-to-earnings ratio than Celularity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celularity	$26.55M	0.87	-$91.72M	-$3.33	N/A
Soligenix	$120K	50.03	-$11.08M	-$0.98	N/A

Celularity has a beta of 0.54, meaning that its share price is 46% less volatile than the broader market. Comparatively, Soligenix has a beta of 1.93, meaning that its share price is 93% more volatile than the broader market.

19.0% of Celularity shares are owned by institutional investors. Comparatively, 3.6% of Soligenix shares are owned by institutional investors. 17.3% of Celularity shares are owned by company insiders. Comparatively, 1.9% of Soligenix shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Soligenix has a net margin of 0.00% compared to Celularity's net margin of -345.45%. Celularity's return on equity of 0.00% beat Soligenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celularity	-345.45%	N/A	-77.94%
Soligenix	N/A	-180.25%	-107.46%

Celularity presently has a consensus price target of $6.00, suggesting a potential upside of 649.25%. Given Celularity's stronger consensus rating and higher possible upside, equities research analysts plainly believe Celularity is more favorable than Soligenix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celularity	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Soligenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Celularity beats Soligenix on 9 of the 14 factors compared between the two stocks.

How does Soligenix compare to Jasper Therapeutics?

Jasper Therapeutics (NASDAQ:JSPR) and Soligenix (NASDAQ:SNGX) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations, profitability and earnings.

Jasper Therapeutics has a beta of 3.02, meaning that its stock price is 202% more volatile than the broader market. Comparatively, Soligenix has a beta of 1.93, meaning that its stock price is 93% more volatile than the broader market.

Soligenix has higher revenue and earnings than Jasper Therapeutics. Jasper Therapeutics is trading at a lower price-to-earnings ratio than Soligenix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jasper Therapeutics	N/A	N/A	-$75.80M	-$1.59	N/A
Soligenix	$120K	50.03	-$11.08M	-$0.98	N/A

Jasper Therapeutics currently has a consensus target price of $8.17, suggesting a potential upside of 1,033.94%. Given Jasper Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Jasper Therapeutics is more favorable than Soligenix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jasper Therapeutics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50
Soligenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Jasper Therapeutics had 7 more articles in the media than Soligenix. MarketBeat recorded 9 mentions for Jasper Therapeutics and 2 mentions for Soligenix. Soligenix's average media sentiment score of 0.00 beat Jasper Therapeutics' score of -0.08 indicating that Soligenix is being referred to more favorably in the news media.

Company	Overall Sentiment
Jasper Therapeutics	Neutral
Soligenix	Neutral

79.9% of Jasper Therapeutics shares are held by institutional investors. Comparatively, 3.6% of Soligenix shares are held by institutional investors. 2.3% of Jasper Therapeutics shares are held by company insiders. Comparatively, 1.9% of Soligenix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Soligenix's return on equity of -180.25% beat Jasper Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jasper Therapeutics	N/A	-884.17%	-143.83%
Soligenix	N/A	-180.25%	-107.46%

Summary

Jasper Therapeutics and Soligenix tied by winning 7 of the 14 factors compared between the two stocks.

Get Soligenix News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SNGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SNGX vs. The Competition

Export

Metric	Soligenix	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$6M	$4.00B	$7.34B	$12.72B
Dividend Yield	N/A	3.63%	2.53%	11.02%
P/E Ratio	-0.41	11.81	270.94	24.14
Price / Sales	50.03	1,381.21	634.79	96.73
Price / Cash	N/A	103.64	78.57	53.12
Price / Book	0.90	16.86	13.14	6.25
Net Income	-$11.08M	-$22.76M	$3.46B	$347.86M
7 Day Performance	2.30%	4.71%	3.23%	1.57%
1 Month Performance	9.10%	12.26%	8.82%	5.24%
1 Year Performance	-87.06%	60.84%	27.70%	17.87%

Soligenix Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SNGX Soligenix	0.8653 of 5 stars	$0.41 +0.1%	N/A	-88.0%	$6M	$120K	N/A	20	Short Interest Decrease
NEUP Neuphoria Therapeutics	2.4246 of 5 stars	$3.98 +3.4%	$21.00 +427.6%	-45.0%	$21.49M	$15.65M	N/A	N/A	Short Interest Decrease High Trading Volume
ALLR Allarity Therapeutics	2.0881 of 5 stars	$1.35 +0.7%	$10.25 +659.3%	+47.2%	$21.48M	$320K	N/A	10
QNTM Quantum Biopharma	0.4643 of 5 stars	$3.34 -9.2%	N/A	-82.1%	$21.38M	N/A	N/A	N/A	Gap Up
CELU Celularity	1.8275 of 5 stars	$0.74 +5.8%	$6.00 +714.4%	-79.6%	$21.33M	$26.55M	N/A	220	News Coverage Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SNGX) was last updated on 8/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Soligenix (SNGX) Competitors

SNGX vs. NEUP, ALLR, QNTM, CELU, and JSPR

How does Soligenix compare to Neuphoria Therapeutics?

Summary

How does Soligenix compare to Allarity Therapeutics?

Summary

How does Soligenix compare to Quantum Biopharma?

Summary

How does Soligenix compare to Celularity?

Summary

How does Soligenix compare to Jasper Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNGX vs. The Competition

Soligenix Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Soligenix (SNGX) Competitors

SNGX vs. NEUP, ALLR, QNTM, CELU, and JSPR

How does Soligenix compare to Neuphoria Therapeutics?

Which has more volatility and risk, SNGX or NEUP?

Do insiders and institutionals hold more shares of SNGX or NEUP?

Which has preferable earnings & valuation, SNGX or NEUP?

Do analysts rate SNGX or NEUP?

Is SNGX or NEUP more profitable?

Does the media refer more to SNGX or NEUP?

Summary

How does Soligenix compare to Allarity Therapeutics?

Do institutionals & insiders have more ownership in ALLR or SNGX?

Do analysts prefer ALLR or SNGX?

Which has higher earnings & valuation, ALLR or SNGX?

Does the media refer more to ALLR or SNGX?

Is ALLR or SNGX more profitable?

Which has more risk and volatility, ALLR or SNGX?

Summary

How does Soligenix compare to Quantum Biopharma?

Do analysts rate QNTM or SNGX?

Which has more risk and volatility, QNTM or SNGX?

Does the media prefer QNTM or SNGX?

Which has higher valuation and earnings, QNTM or SNGX?

Do insiders & institutionals hold more shares of QNTM or SNGX?

Is QNTM or SNGX more profitable?

Summary

How does Soligenix compare to Celularity?

Does the media refer more to CELU or SNGX?

Which has higher valuation and earnings, CELU or SNGX?

Which has more volatility & risk, CELU or SNGX?

Do insiders and institutionals hold more shares of CELU or SNGX?

Is CELU or SNGX more profitable?

Do analysts prefer CELU or SNGX?

Summary

How does Soligenix compare to Jasper Therapeutics?

Which has more risk & volatility, JSPR or SNGX?

Which has better earnings and valuation, JSPR or SNGX?

Do analysts recommend JSPR or SNGX?

Does the media favor JSPR or SNGX?

Do insiders & institutionals believe in JSPR or SNGX?

Is JSPR or SNGX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNGX vs. The Competition

Soligenix Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools